Multifunctional Biomimetic Nanotherapeutics for Anti‐Oxidative and Anti‐Inflammatory Synergistic Therapy of Corneal Neovascularization

ABSTRACT Corneal neovascularization (CNV) is a debilitating ocular surface disease that severely compromises visual function and carries a significant risk of vision loss. Despite its clinical impact, the development of effective and safe pharmacological treatments for CNV remains an unmet medical n...

Full description

Saved in:
Bibliographic Details
Main Authors: Shundong Cai, Mengdie Li, Jinfa Ye, Mingyou Zhang, Jingbin Zhuang, Yuhang Cheng, Hongjin Li, Lang Ke, Xingyuan Wei, Yun Han, Huanhuan Liu, Gang Liu, Chengchao Chu
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Aggregate
Subjects:
Online Access:https://doi.org/10.1002/agt2.70034
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849686281660923904
author Shundong Cai
Mengdie Li
Jinfa Ye
Mingyou Zhang
Jingbin Zhuang
Yuhang Cheng
Hongjin Li
Lang Ke
Xingyuan Wei
Yun Han
Huanhuan Liu
Gang Liu
Chengchao Chu
author_facet Shundong Cai
Mengdie Li
Jinfa Ye
Mingyou Zhang
Jingbin Zhuang
Yuhang Cheng
Hongjin Li
Lang Ke
Xingyuan Wei
Yun Han
Huanhuan Liu
Gang Liu
Chengchao Chu
author_sort Shundong Cai
collection DOAJ
description ABSTRACT Corneal neovascularization (CNV) is a debilitating ocular surface disease that severely compromises visual function and carries a significant risk of vision loss. Despite its clinical impact, the development of effective and safe pharmacological treatments for CNV remains an unmet medical need. The pathogenesis of CNV is largely driven by inflammation and excessive oxidative stress. In this study, we introduce a novel nanotherapeutic strategy utilizing vanadium carbide quantum dots (V2C QDs) with intrinsic nanozyme properties, co‐encapsulated with a plasmid encoding interleukin‐10 (IL‐10) within a biomimetic metal‐organic framework (MOF) for the treatment of CNV. To enhance targeting and biocompatibility, the nanoparticles (NPs) are further coated with mesenchymal stem cell (MSC)‐derived cell membrane vesicles (CMVs), yielding the final nanomedicine designated as MOF‐V2C‐Plasmid@CMVs (MVPC). In vitro studies demonstrate that MVPC NPs effectively scavenge reactive oxygen species (ROS) induced by tert‐butyl hydroperoxide (tBOOH), mitigating oxidative stress. Moreover, the successful delivery and expression of the IL‐10 plasmid in RAW264.7 cells result in elevated IL‐10 secretion, showcasing robust anti‐inflammatory activity. The CMV coating facilitates targeted delivery, enabling the efficient accumulation of MVPC NPs in the CNV region following topical administration via eye drops. In vivo experiments in CNV model rats reveal that MVPC nanotherapeutics significantly suppress neovascularization without inducing adverse effects. Collectively, this study provides proof of concept for a multifunctional nanotherapeutic platform targeting CNV, offering a promising and clinically translatable approach for the treatment of this challenging ocular disease.
format Article
id doaj-art-bae0b2b555dd415bb7397c2eb266d2db
institution DOAJ
issn 2692-4560
language English
publishDate 2025-06-01
publisher Wiley
record_format Article
series Aggregate
spelling doaj-art-bae0b2b555dd415bb7397c2eb266d2db2025-08-20T03:22:45ZengWileyAggregate2692-45602025-06-0166n/an/a10.1002/agt2.70034Multifunctional Biomimetic Nanotherapeutics for Anti‐Oxidative and Anti‐Inflammatory Synergistic Therapy of Corneal NeovascularizationShundong Cai0Mengdie Li1Jinfa Ye2Mingyou Zhang3Jingbin Zhuang4Yuhang Cheng5Hongjin Li6Lang Ke7Xingyuan Wei8Yun Han9Huanhuan Liu10Gang Liu11Chengchao Chu12Xiamen University affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine Xiamen University Xiamen ChinaXiamen University affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine Xiamen University Xiamen ChinaXiamen University affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine Xiamen University Xiamen ChinaXiamen University affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine Xiamen University Xiamen ChinaXiamen University affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine Xiamen University Xiamen ChinaXiamen University affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine Xiamen University Xiamen ChinaXiamen University affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine Xiamen University Xiamen ChinaXiamen University affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine Xiamen University Xiamen ChinaXiamen University affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine Xiamen University Xiamen ChinaXiamen University affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine Xiamen University Xiamen ChinaState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry‐Education Integration in Vaccine Research, Fujian Engineering Research Center of Molecular Theranostic Technology, Center for Molecular Imaging and Translational Medicine, School of Public Health Xiamen University Xiamen ChinaState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, National Innovation Platform for Industry‐Education Integration in Vaccine Research, Fujian Engineering Research Center of Molecular Theranostic Technology, Center for Molecular Imaging and Translational Medicine, School of Public Health Xiamen University Xiamen ChinaXiamen University affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine Xiamen University Xiamen ChinaABSTRACT Corneal neovascularization (CNV) is a debilitating ocular surface disease that severely compromises visual function and carries a significant risk of vision loss. Despite its clinical impact, the development of effective and safe pharmacological treatments for CNV remains an unmet medical need. The pathogenesis of CNV is largely driven by inflammation and excessive oxidative stress. In this study, we introduce a novel nanotherapeutic strategy utilizing vanadium carbide quantum dots (V2C QDs) with intrinsic nanozyme properties, co‐encapsulated with a plasmid encoding interleukin‐10 (IL‐10) within a biomimetic metal‐organic framework (MOF) for the treatment of CNV. To enhance targeting and biocompatibility, the nanoparticles (NPs) are further coated with mesenchymal stem cell (MSC)‐derived cell membrane vesicles (CMVs), yielding the final nanomedicine designated as MOF‐V2C‐Plasmid@CMVs (MVPC). In vitro studies demonstrate that MVPC NPs effectively scavenge reactive oxygen species (ROS) induced by tert‐butyl hydroperoxide (tBOOH), mitigating oxidative stress. Moreover, the successful delivery and expression of the IL‐10 plasmid in RAW264.7 cells result in elevated IL‐10 secretion, showcasing robust anti‐inflammatory activity. The CMV coating facilitates targeted delivery, enabling the efficient accumulation of MVPC NPs in the CNV region following topical administration via eye drops. In vivo experiments in CNV model rats reveal that MVPC nanotherapeutics significantly suppress neovascularization without inducing adverse effects. Collectively, this study provides proof of concept for a multifunctional nanotherapeutic platform targeting CNV, offering a promising and clinically translatable approach for the treatment of this challenging ocular disease.https://doi.org/10.1002/agt2.70034anti‐inflammatory therapyanti‐oxidative therapybiomimetic nanomedicinecorneal neovascularizationvanadium carbide
spellingShingle Shundong Cai
Mengdie Li
Jinfa Ye
Mingyou Zhang
Jingbin Zhuang
Yuhang Cheng
Hongjin Li
Lang Ke
Xingyuan Wei
Yun Han
Huanhuan Liu
Gang Liu
Chengchao Chu
Multifunctional Biomimetic Nanotherapeutics for Anti‐Oxidative and Anti‐Inflammatory Synergistic Therapy of Corneal Neovascularization
Aggregate
anti‐inflammatory therapy
anti‐oxidative therapy
biomimetic nanomedicine
corneal neovascularization
vanadium carbide
title Multifunctional Biomimetic Nanotherapeutics for Anti‐Oxidative and Anti‐Inflammatory Synergistic Therapy of Corneal Neovascularization
title_full Multifunctional Biomimetic Nanotherapeutics for Anti‐Oxidative and Anti‐Inflammatory Synergistic Therapy of Corneal Neovascularization
title_fullStr Multifunctional Biomimetic Nanotherapeutics for Anti‐Oxidative and Anti‐Inflammatory Synergistic Therapy of Corneal Neovascularization
title_full_unstemmed Multifunctional Biomimetic Nanotherapeutics for Anti‐Oxidative and Anti‐Inflammatory Synergistic Therapy of Corneal Neovascularization
title_short Multifunctional Biomimetic Nanotherapeutics for Anti‐Oxidative and Anti‐Inflammatory Synergistic Therapy of Corneal Neovascularization
title_sort multifunctional biomimetic nanotherapeutics for anti oxidative and anti inflammatory synergistic therapy of corneal neovascularization
topic anti‐inflammatory therapy
anti‐oxidative therapy
biomimetic nanomedicine
corneal neovascularization
vanadium carbide
url https://doi.org/10.1002/agt2.70034
work_keys_str_mv AT shundongcai multifunctionalbiomimeticnanotherapeuticsforantioxidativeandantiinflammatorysynergistictherapyofcornealneovascularization
AT mengdieli multifunctionalbiomimeticnanotherapeuticsforantioxidativeandantiinflammatorysynergistictherapyofcornealneovascularization
AT jinfaye multifunctionalbiomimeticnanotherapeuticsforantioxidativeandantiinflammatorysynergistictherapyofcornealneovascularization
AT mingyouzhang multifunctionalbiomimeticnanotherapeuticsforantioxidativeandantiinflammatorysynergistictherapyofcornealneovascularization
AT jingbinzhuang multifunctionalbiomimeticnanotherapeuticsforantioxidativeandantiinflammatorysynergistictherapyofcornealneovascularization
AT yuhangcheng multifunctionalbiomimeticnanotherapeuticsforantioxidativeandantiinflammatorysynergistictherapyofcornealneovascularization
AT hongjinli multifunctionalbiomimeticnanotherapeuticsforantioxidativeandantiinflammatorysynergistictherapyofcornealneovascularization
AT langke multifunctionalbiomimeticnanotherapeuticsforantioxidativeandantiinflammatorysynergistictherapyofcornealneovascularization
AT xingyuanwei multifunctionalbiomimeticnanotherapeuticsforantioxidativeandantiinflammatorysynergistictherapyofcornealneovascularization
AT yunhan multifunctionalbiomimeticnanotherapeuticsforantioxidativeandantiinflammatorysynergistictherapyofcornealneovascularization
AT huanhuanliu multifunctionalbiomimeticnanotherapeuticsforantioxidativeandantiinflammatorysynergistictherapyofcornealneovascularization
AT gangliu multifunctionalbiomimeticnanotherapeuticsforantioxidativeandantiinflammatorysynergistictherapyofcornealneovascularization
AT chengchaochu multifunctionalbiomimeticnanotherapeuticsforantioxidativeandantiinflammatorysynergistictherapyofcornealneovascularization